Key Takeaways
- Sanders aims to pressure Novo Nordisk to cut U.S. prices for Ozempic and Wegovy.
- Novo Nordisk’s CEO will testify before the Senate in September.
- Sanders plans to introduce legislation targeting drug price negotiations and out-of-pocket costs.
What Happened?
Senator Bernie Sanders expressed confidence that Novo Nordisk can be pressured to reduce the U.S. prices of its popular weight-loss drugs, Ozempic and Wegovy. Sanders plans to publicly shame Novo Nordisk over its pricing compared to other countries.
Novo Nordisk’s CEO Lars Jorgensen is set to testify before the Senate Committee on Health, Education, Labor and Pensions (HELP) in September. This follows Sanders’ previous success in getting insulin prices reduced by pressuring Novo, Eli Lilly, and Sanofi last year.
Why It Matters?
High drug prices significantly impact healthcare costs in the U.S. While more than 80% of insured Americans pay $25 or less per month for these drugs, the overall high prices inflate insurance premiums and hospital costs. Novo Nordisk’s Ozempic lists for $935.77 per month in the U.S., compared to $155 in Canada.
Sanders argues that reducing these prices could ease financial burdens for American consumers and healthcare systems. The pharmaceutical market for weight-loss drugs is projected to exceed $100 billion by the end of the decade, making this issue even more pressing.
What’s Next?
Expect heightened scrutiny of Novo Nordisk in the upcoming Senate hearing. Sanders plans to introduce legislation to expand the maximum number of drugs eligible for Medicare price negotiations and extend the $2,000 annual cap on out-of-pocket costs beyond Medicare.
Additionally, Sanders will focus on pharmacy benefit managers, who play a role in drug pricing but cannot be solely blamed for high costs. Investors should watch for potential regulatory changes that could affect pharmaceutical companies’ pricing strategies and market dynamics.
